Brief: Arcellx Announces Presentation Of New Clinical Data From Its Cart-Ddbcma Phase 1 Trial In Patients With Relapsed Or Refractory Multiple Myeloma At The 64Th Ash Annual Meeting And Exposition
03/11/2022 15:03
Nov 3 (Reuters) - Arcellx Inc ACLX.O :
* ARCELLX ANNOUNCES PRESENTATION OF NEW CLINICAL DATA FROM
ITS
CART-DDBCMA PHASE 1 TRIAL IN PATIENTS WITH RELAPSED OR
REFRACTORY MULTIPLE MYELOMA AT THE 64TH ASH ANNUAL MEETING AND
EXPOSITION
Source text for Eikon: ID:nPn1c8204a
Further company coverage: ACLX.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Arcellx
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 02:18 PM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Gilead Extends Tender Offer To Acquire Arcellx
U.S. RESEARCH ROUNDUP-Arcellx, Costar Group, Magnite